RECRUITING Not applicable ClinicalTrials.gov

Combined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism

Sponsor: University Hospital, Strasbourg, France • ClinicalTrials.gov ID: NCT06576713

Registry updated: 2026-08-21

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Despite the increasing availability and advances in the analysis of high-throughput DNA sequencing, the majority of patients with early-onset or familial parkinsonism remain without a molecular diagnosis. Studying the genetic forms of parkinsonian syndromes presents numerous clinical, scientific and therapeutic interests. In clinical practice, identifying the genetic cause in a patient allow to provide genetic counseling and estimate the risk of recurrence in their relatives. Establishing correlations between the genotype and phenotype of patients with genetically determined parkinsonism, allow to better anticipate the evolution of the disease, or even to highlight biomarkers during the presymptomatic phases. Finally, the proteins encoded by the genes implicated in familial parkinsonism represent potential therapeutic targets likely to be modulated by neuroprotective pharmacological agents, even in sporadic Parkinson's disease. In this work,investigators aimed at elucidating the missing genetic causes of parkinsonism through the application of combined RNA and whole genome sequencing.

Interventions

Combiner whole genome and RNA sequencing (Diagnostic test)
High-throughput DNA and RNA sequencing

Eligibility criteria

Inclusion Criteria: * Extrapyramidal syndrome beginning before or at the age of 40 or associated with a family history: * Dopaminergic denervation proven by ioflupane brain scintigraphy (DaTscan®) * DNAs from both asymptomatic parents available in biobank * Subject affiliated to a social protection health insurance scheme or beneficiary or beneficiary * Subject able to understand the objectives and risks related to the research and to give dated and signed informed consent Exclusion Criteria: * \- Contraindication for performing a superficial skin biopsy provided for by the protocol * Molecular cause of parkinsonism previously identified * Absence of prior genetic exploration by high-throughput DNA sequencing * Patient with late-onset sporadic parkinsonian syndrome (\> 40 years) without family history * Patient with Parkinson's syndrome associated with a specific diagnosis (genetic or non-genetic pathology: exposure to neuroleptics, toxic origin) * Impossibility of providing the subject with informed information * Subject under judicial protection * Subject under guardianship or curatorship

Conditions

Parkinson's Disease

Locations

Hôpitaux Universitaires de Strasbourg — Strasbourg, Grand Est, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment